

RECEIVED

Oct 19 2026

S.C. SUPREME COURT

EXHIBIT 1

The Supreme Court of South Carolina

John A. Tibbs and Margaret B. Tibbs, Plaintiffs,

v.

3M Company; 4520 Corp., Inc.; A.O. Smith Corporation; A.W. Chesterton Company; ABB, Inc.; Air & Liquid Systems Corporation; AiW-2010 Wind Down Corp.; Amentum Environment & Energy, Inc.; Anchor/Darling Valve Company; Armstrong International, Inc.; Asbestos Corporation Limited; ASCO, L.P.; Atlas Asbestos Co; Atlas Turner, Inc.; AWT Air Company, Inc.; Bahnson, Inc.; Banner Industries International, Inc.; Banner Industries, LLC; Banner Industries of N.E., Inc.; Barretts Minerals, Inc.; Beaty Investments, Inc.; Bechtel Corporation; The Bonitz Company; Brand Insulations, Inc.; BW/IP Inc.; Canvas Ct, LLC; Cape PLC; Carboline Company; CB&I Laurens, Inc.; Cleaver-Brooks, Inc.; Consolidated Electrical Distributors, Inc.; Copes-Vulcan, Inc.; Covil Corporation; Crane Instrumentation & Sampling, Inc.; Crosby Valve, LLC; Daniel International Corporation; Davis Mechanical Contractors, Inc.; Dezurik, Inc.; Duke Energy Carolinas, LLC; Duke Energy Corporation; Eaton Corporation; Ellington Insulation Company, Inc.; Emerson Electric Co.; Fisher Controls International LLC; Flame Refractories, Inc.; Flowserve Corporation; Flowserve US, Inc.; Fluor Constructors International; Fluor Constructors International, Inc.; Fluor Daniel Services Corporation; Fluor Enterprises, Inc.; FMC Corporation; Foster Wheeler Energy Corporation; Gardner Denver Nash, LLC; General Boiler Casing Company, Inc.; General Cable Corporation; General Cable Industries, Inc.; General Electric Company; Gould Electronics, Inc.; Goulds Pumps, Incorporated; Goulds Pumps LLC; Great Barrier Insulation Co.; Grinnell LLC; Hajoca Corporation; Howden North America, Inc.; HPC Industrial Services, LLC; IMO Industries, Inc.; ITT LLC;

Joy Global Underground Mining LLC; K-Mac Services Incorporated; Metropolitan Life Insurance Company; Mine Safety Appliances Company, LLC; MP Supply, Inc.; The Nash Engineering Company; Occidental Chemical Corporation; Paramount Global; Patterson Pump Company; PECW Holding Company; Pfizer, Inc.; Piedmont Insulation, Inc.; Plastics Engineering Company; Presnell Insulation Co., Inc.; Redco Corporation; Riley Power Inc.; Rockwell Automation, Inc.; RSCC Wire & Cable LLC; Schneider Electric USA, Inc.; Sequoia Ventures, Inc.; Spirax Sarco, Inc.; SPX Corporation; Stafford Insulation Company; Standard Insulation Company Of N.C., Inc.; Starr Davis Company, Inc.; Starr Davis Company of S.C., Inc.; Sterling Fluid Systems (USA) LLC; TE Wire & Cable LLC; Thermo Electric Company, Inc.; Union Carbide Corporation; Valves And Controls Us, Inc.; Velan Valve Corp.; Viking Pump, Inc.; Vistra Intermediate Company LLC; The William Powell Company Wind Up, Ltd.; Yuba Heat Transfer LLC; Zurn Industries, LLC, Defendants,

and

Cape PLC, individually and as successor in interest to Cape Asbestos Company Limited, by and through its duly appointed Receiver Peter D. Protopapas, Third-Party Plaintiff, Respondent,

v.

Anglo American PLC, individually and as successor in interest to Anglo American Corporation of South Africa LTD., De Beers PLC, individually and as successor in interest to De Beers S.A., De Beers Centenary AG, De Beers Consolidated Mines Ltd., n/k/a De Beers Consolidated Mines Proprietary Ltd., De Beers UK Ltd., De Beers Jewellers LTD., De Beers Jewellers US, Inc., Anglo American US Holdings Inc., Element Six US Corp., Element Six Technologies US Corp., Element Six Technologies (OR) Corp., First Mode Holdings, Inc.,

Platinum Guild International (U.S.A.) Jewelry Inc.,
Lightbox Jewelry Inc., Forevermark US Inc., Anglo
American Crop Nutrients (U.S.A.) LLC, Charter
Consolidated Ltd., ESAB Corporation, Central Mining &
Investment Corporation Ltd., Cape Holdco Ltd., The Law
Debenture Corporation PLC, Cape Industrial Services
Group Ltd., Mohed Altrad, Altrad UK Ltd., Cape UK
Holdings Newco Ltd., Altrad Services, Ltd., f/k/a Cape
Industrial Services Ltd., Altrad Investment Authority
S.A.S., Sparrows Offshore Group Ltd., Hawk Bidco US
Inc., ArranCo US, LLC, Sparrows Offshore, LLC, and
The Sparrows Group, LLC, Third-Party Defendants,

Of which Mohed Altrad, Altrad Investment Authority
SAS, Charter Consolidated Ltd., ESAB Corporation, and
Central Mining & Investment Corporation Ltd. are the
Petitioners.

Appellate Case Nos:

2024-001423, 2024-001499, 2024-000916, 2024-002114,
2024-002116, 2024-002117, 2025-000052

ORDER



We have before us seven petitions for writs of certiorari filed in this Court under Rule 242 of the South Carolina Appellate Court Rules. Each petition was filed by some combination of Petitioners Mohed Altrad, Altrad Investment Authority SAS, Charter Consolidated Ltd., ESAB Corporation, and Central Mining & Investment Corporation Ltd., and each arises from an order of the court of appeals dismissing an appeal on the ground the order appealed from was not immediately appealable. Each appeal and now each petition challenges some aspect of the circuit court's order appointing Peter D. Protopapas as Receiver for Defendant Cape PLC. We deny the petitions in cases 2024-000916, 2024-002114, 2024-002116, 2024-002117, and 2025-000052. In cases 2024-001423 and 2024-001499, we convert the petitions to common law writs of certiorari, and grant them pursuant to article V, section 5 of the South Carolina Constitution and section 14-3-310 of the South

Carolina Code (2017). We dispense with any briefing and remand the cases to the circuit court for all purposes, specifically including:

- (A) On May 21, this Court filed its opinion in *Welch v. Atlas Turner, Inc.*, Op. No. 28284 (S.C. Sup. Ct. filed May 21, 2025) (Howard Adv. Sh. No. 19 at 12). In that opinion, we analyzed the circuit court's jurisdiction to appoint a receiver, discussed the factual basis on which such an order must be based, and set forth limitations on the receiver's scope of authority. We also made it clear that appointing a receiver before judgment is permissible only in the "rarest" and "most extraordinary" cases. We now direct the circuit court to:
- 1) Ensure the receiver has been authorized to conduct its work by an order filed in the specific case as to which the work is to take place. The receiver is not to be authorized to conduct work as to a case in which no receiver appointment order has been filed.
 - 2) Ensure that such an order is based on findings of fact sufficient under *Welch* to justify the order, and that the receiver's scope of authority is limited as set forth in *Welch*.
 - 3) To the extent the circuit court intends to authorize the work of a receiver based on facts not found sufficient in *Welch*, or to authorize a scope of work not approved in *Welch*, the circuit court should make specific findings of fact and conclusions of law the circuit court finds justify its action.
- (B) It has come to our attention there may be motions filed in this case and other asbestos cases that have not been ruled on by the circuit court. Specifically, we understand there is a pending motion to dissolve the receivership filed September 15, 2023, and a pending motion to reconsider a "clarifying" order filed November 15, 2024, both in *Park v. Armstrong International, Inc., et al.*, 2021-CP-40-2727. To the extent that is true, we direct the circuit court to either rule on all pending motions or set forth an explanation of the reasons the court determines it should not rule at this time.
- (C) We ask that the circuit court provide this Court with a report on its progress on matters (A) and (B), including the current status of *Park* and all asbestos cases in which a receiver has been appointed, every 30 days until further order of this Court.

We address one final matter. Over the last few years, the court of appeals and this Court have received dozens of interlocutory appeals in asbestos cases such as this one. In the vast majority of those cases, the court of appeals dismissed the appeal

because the order was not an immediately appealable order, and we denied certiorari because we agreed the dismissal was proper. In fact, many of the appeals from those orders have bordered on frivolous. We will rule at a later time on any currently pending motion for sanctions, and any further frivolous appeals in these cases from interlocutory orders that are not immediately appealable will result in sanctions. In addition, the parties' filings at the court of appeals and this Court have been unnecessarily antagonistic, predominated by what one litigant in these petitions characterized as "sniping" at each other on matters that have nothing to do with the merits of the appeal. No party gains an advantage in the exercise of this inappropriate behavior. This Court and the court of appeals will not tolerate it any further. Appeals will be summarily dismissed, or requested relief will be summarily granted, if any party continues with this inappropriate behavior. Our intention is to reach and address the merits of issues properly before us without the distraction of unnecessary sniping by the lawyers, and if the lawyers persist in this sniping, appropriate sanctions will be imposed.

	_____	C.J.
	_____	J.
	_____	J.
D. Manini	_____	J.

Verdin, J., not participating.

Columbia, South Carolina
June 26, 2025

cc: Matthew Todd Carroll
Kevin A. Hall
Mary Elizabeth O'Neill
Shanon N. Peake
G. Murrell Smith, Jr.
John Thomas Lay, Jr.
Gray Thomas Culbreath
Lindsay Anne Joyner
Laura Watkins Jordan
Eleanor Lasseigne Jones
Jonathan M. Robinson
Brian Montgomery Barnwell
Amelia Morgan Farmer
Ioannis (Ian) George Conits
Peter Demos Protopapas
William James Blount
A. Victor Rawl, Jr.
John S. Nichols
Steven James Pugh
Benjamin Palmer Carlton
Carmen Vaughn Ganjehsani
Ashwin Ray Sanzgiri
John Kenneth Chandler
The Honorable Jeanette W. McBride

EXHIBIT 2

☒ IN THE CIRCUIT COURT OF THE ELEVENTH JUDICIAL CIRCUIT IN AND FOR MIAMI-DADE COUNTY, FLORIDA. ☐ IN THE COUNTY COURT IN AND FOR MIAMI-DADE COUNTY, FLORIDA.		
DIVISION ☒ CIVIL ☐ DISTRICTS ☐ OTHER	SUMMONS 20 DAY CORPORATE SERVICE (a) GENERAL FORMS	CASE NUMBER 2026-134385-CC-26
PLAINTIFF(S) JOHNSON & JOHNSON	VS. DEFENDANT(S) DEAN OMAR BRANHAM SHIRLEY, LLP	SERVICE
THE STATE OF FLORIDA: To Each Sheriff of the State: YOU ARE COMMANDED to serve this summons and copy of the complaint or petition in this action on defendant(s): <u>DEAN OMAR BRANHAM SHIRLEY, LLP</u> <u>1801 N Lamar St, Suite 300, Dallas, TX 75202</u> Each defendant is required to serve written defense to the complaint or petition on Plaintiff's Attorney: <u>Josh Fordin</u> whose address is: <u>830 Brickell Plaza, Miami, FL 33131</u>		CLOCK IN
within 20 days " <u>Except when suit is brought pursuant to s. 768.28, Florida Statutes, if the State of Florida, one of its agencies, or one of its officials or employees sued in his or her official capacity is a defendant, the time to respond shall be 40 days. When suit is brought pursuant to, 768.28, Florida Statutes, the time to respond shall be 30 days.</u> after service of this summons on that defendant , exclusive of the day of service, and to file the original of the defenses with the clerk of this court either before service on Plaintiff's attorney or immediately thereafter. A defendant may either file the response electronically by using the Florida Courts E-filing Portal (MyFLCourtAccess.com), or by filing the written response with the clerk of court. If a defendant fails to do so, a default will be entered against that defendant for the relief demanded in the complaint or petition.		
JUAN FERNANDEZ-BARQUIN CLERK OF THE COURT AND COMPTROLLER MIAMI-DADE COUNTY CIRCUIT AND COUNTY COURTS	BY: _____ DEPUTY CLERK	DATE
AMERICANS WITH DISABILITIES ACT OF 1990 ADA NOTICE <p> "If you are a person with a disability who needs any accommodation in order to participate in this proceeding, you are entitled, at no cost to you, to the provision of certain assistance. Please contact ADA Coordinator, Lawson E. Thomas Courthouse Center, 175 NW 1st Avenue, Suite 2400, Miami, FL 33128; Telephone (305) 349-7175; TDD (305) 349-7174, Email ADA@jud11.flcourts.org; or via Fax at (305) 349-7355, at least seven (7) days before your scheduled court appearance, or immediately upon receiving this notification if the time before the scheduled appearance is less than seven (7) days; if you are hearing or voice impaired, call 711." </p>		

IN THE CIRCUIT COURT OF THE ELEVENTH
JUDICIAL CIRCUIT IN AND FOR MIAMI-
DADE COUNTY, FLORIDA

GENERAL JURISDICTION DIVISION

CASE NO.

JOHNSON & JOHNSON,

Plaintiff,

v.

DEAN OMAR BRANHAM SHIRLEY, LLP,

Defendant.

COMPLAINT FOR PURE BILL OF DISCOVERY

Plaintiff, Johnson & Johnson (“J&J”), files this Complaint for a pure bill of discovery to obtain information from Defendant Dean Omar Branham Shirley, LLP (“DOBS”) regarding lobbying activities undertaken by, on behalf of, or for the benefit of DOBS and its various personal injury clients, relating to the regulation of talc used in cosmetics and consumer products. Those activities and the information concerning them are material and necessary to Plaintiff’s defense in pending and anticipated litigation, and the information is exclusively within DOBS’s possession and unavailable through ordinary discovery mechanisms. Plaintiff therefore states as follows:

NATURE OF THE ACTION

1. Plaintiff brings this pure bill of discovery to compel Defendant to disclose information regarding its efforts to lobby, influence, advocate for or against, or otherwise attempt to affect legislation, regulation, rulemaking, or agency action relating to talc used in cosmetics or consumer products, including but not limited to efforts directed at federal, state, or local government officials, legislators, regulators, or agencies, as well as any information in its

possession regarding such efforts undertaken on behalf of it, its various talc litigation clients, or other law firms representing plaintiffs in talcum powder litigation.

JURISDICTION, PARTIES & VENUE

2. This Court has jurisdiction over the subject matter of this action pursuant to section 26.012(2)(c), Florida Statutes, establishing that circuit courts have exclusive jurisdiction “in all cases in equity.”

3. Defendant DOBS is a limited liability partnership with its principal place of business located in Dallas, Texas. DOBS is a law firm involved in personal injury litigation, including nationwide talc and asbestos litigation. It provides legal representation to tort plaintiffs, including multiple Florida residents with lawsuits pending in the circuit courts of Florida, alleging that they developed various cancers, including mesothelioma, as a result of their exposure to asbestos allegedly contained in talc-based cosmetic powder products.

4. This Court has specific personal jurisdiction over DOBS pursuant to section 48.193(1)(a), Florida Statutes. DOBS is subject to jurisdiction under section 48.193(1)(a)1. because it is “[o]perating, conducting, engaging in, or carrying on a business or business venture in this state.” Specifically, DOBS actively solicits and represents Florida residents as clients in talc and asbestos personal injury litigation, maintains an ongoing attorney-client relationship with multiple Florida residents, files pleadings and makes appearances in Florida courts on a regular and continuing basis, and advertises its legal services to Florida residents through its website and other channels. DOBS represents plaintiffs in talc cases against J&J currently pending in Florida, including *Renwick v. Johnson & Johnson et al.*, Case No. 23-011345-CA-01 (Miami-Dade County), and *Fisher v. Johnson & Johnson et al.*, Case No. CACE-24-005907-CA-24 (Broward County) (collectively, the “Florida Litigation”). The exercise of jurisdiction comports with

constitutional due process because DOBS has purposefully availed itself of the privilege of conducting activities in Florida, the claims asserted in this action arise out of or relate to DOBS's Florida contacts, and the exercise of jurisdiction is reasonable given DOBS's systematic litigation presence in this forum.

5. Plaintiff J&J is a corporation organized and existing under the laws of the State of New Jersey, with its principal place of business in New Jersey. J&J is a holding company that, through its subsidiaries, develops, manufactures, and sells products in the United States, including Florida. J&J is a named defendant in talc and asbestos personal injury litigation nationwide, including in South Carolina and Florida.

6. Venue is proper in this Court because "a nonresident over whom personal jurisdiction can be obtained consistent with constitutional considerations can, at a plaintiff's election, be sued in *any* county in this state..." *Metnick & Levy, P.A. v. Seuling*, 123 So. 3d 639, 642 (Fla. 4th DCA 2013) (emphasis added) (internal citations omitted).

BACKGROUND

I. Talc Litigation

7. DOBS is a law firm that represents plaintiffs against J&J and other defendants in talc litigation in various jurisdictions throughout the United States, including cases filed in this state as well as the South Carolina talc-mesothelioma cancer multi-county litigation. In South Carolina, DOBS represents plaintiffs in cases pending before the Court of Common Pleas for the Fifth Judicial Circuit, including *Barnett v. Johnson & Johnson, et al.*, Case No. 2026-CP-40-01257, and *Gerken v. Avon Products, Inc., et al.*, Case No. 2023-CP-40-06111 (the "South Carolina Litigation").

8. On August 17, 2026, DOBS served Rule 30(b)(6) deposition notices and accompanying document requests on J&J and its co-defendant Kenvue Inc. (“Kenvue”) in the South Carolina Litigation. It served amended notices on September 2, 2026. The notices seek corporate representative testimony and documents regarding, among other things, J&J’s communications with the Department of Health & Human Services (“HHS”), the Food and Drug Administration (“FDA”), and the Executive Branch, as well as with trade organizations, concerning the Consolidated Appropriations Act, 2023; the Modernization of Cosmetics Regulation Act of 2022 (“MoCRA”); the FDA’s proposed and since-withdrawn asbestos testing rule; the FDA’s May 20, 2025 Expert Panel on Talc; and European health agencies’ assessments of a potential ban on talc. J&J had already produced a corporate representative, Dr. Edwin Kuffner, who testified on regulatory topics, including the Expert Panel on Talc, at a two-day deposition in *Gerken* on September 10 and 11, 2025. On September 2, 2026, J&J and Kenvue moved to quash the notices and for a protective order, and on September 16, 2026, J&J served written objections to the amended deposition notices. On October 2, 2026, the court denied the motion as to the lobbying and regulatory topics. It ordered J&J and Kenvue to produce responsive documents by October 14, 2026, and to produce a prepared Rule 30(b)(6) witness on October 23 or October 29, 2026. DOBS’s notices expressly reserve the right to use the resulting testimony and exhibits “for any purpose, including at trial in this and in any subsequent matter.” On information and belief, DOBS intends to use this discovery at trial, not only in South Carolina but also in litigation brought by its clients in other jurisdictions, including the Florida Litigation, to portray Plaintiff as seeking to suppress or manipulate governmental oversight of talc-based cosmetic products.

II. DOBS’s Lobbying Efforts Relating To The Cosmetics Industry

9. On information and belief, DOBS, either itself or in coordination with third parties, has engaged in lobbying efforts to influence federal legislative and regulatory actions, including the Consolidated Appropriations Act, 2023; MoCRA; the FDA's proposed and since-withdrawn rule entitled "Testing Methods for Detecting and Identifying Asbestos in Talc-Containing Cosmetic Products" (the "Proposed Rule"); and the FDA's May 20, 2025 event titled "Expert Panel on Talc." These are the same legislative and regulatory matters on which DOBS has compelled discovery from J&J in the South Carolina Litigation.

10. In December 2022, Congress passed the Consolidated Appropriations Act, 2023, an omnibus spending and appropriations bill. *See* Pub. L. No. 117-328, 136 Stat. 4459 (2022). Congress enacted MoCRA as part of that legislation. MoCRA directs the FDA to issue regulations establishing standardized testing methods for detecting and identifying asbestos in talc-containing cosmetic products.

11. On December 27, 2024, the FDA published the Proposed Rule, which purported to establish a methodology for testing cosmetic talc for asbestos. *See* 89 Fed. Reg. 105,490 (Dec. 27, 2024). The Proposed Rule was never finalized, and on November 28, 2025, the FDA formally withdrew it. *See* 90 Fed. Reg. 54,603 (Nov. 28, 2025).

12. On May 20, 2025, the FDA held an event titled "Expert Panel on Talc" (the "Roundtable"). At the Roundtable, FDA Commissioner Martin Makary convened nine individuals characterized as experts, several of whom are paid litigation consultants retained by plaintiffs' counsel in pending talc cases across the country. The Roundtable did not include any representatives of the defense or the regulated industry and offered no opportunity for public comment. Nevertheless, the Roundtable purported to offer several opinions on the issues of cosmetic talc and asbestos under the guise of FDA authority. Nothing said at the Roundtable

constituted the official position of the FDA, and the FDA has taken no regulatory or enforcement action in connection with it.

13. Each of these legislative and regulatory events occurred after J&J discontinued manufacturing and selling talc-based cosmetic powder products in the United States in 2020 and after it announced the cessation of such sales globally. Moreover, the Proposed Rule was never finalized or implemented.

14. On information and belief, DOBS participates in or coordinates with professional, industry, and advocacy organizations focused on alleged talc safety issues. On information and belief, through these affiliations, DOBS or organizations with which it is associated may have leveraged industry conferences, submitted or supported comments during federal rulemaking proceedings, supported scientific research and publications favorable to plaintiffs' litigation theories, and coordinated public advocacy campaigns to advance positions favorable to DOBS's litigation strategy and to shape the regulatory and scientific discourse surrounding talc-based cosmetic products in a manner that benefits DOBS and its clients at trial.

15. On information and belief, DOBS, directly or through intermediaries, third-party organizations, and coordinated efforts with other plaintiffs' firms at the federal, state, and local levels, has sought to influence regulatory agencies to classify talc-based cosmetic products, including J&J's products, as carcinogenic, to tighten restrictions on the use of cosmetic talc, and to generate adverse regulatory findings that could be deployed at trial to benefit its litigation strategy against Plaintiff. On information and belief, these efforts include direct and indirect communications with FDA officials and staff regarding the Proposed Rule; participation in or coordination with organizations that submitted public comments on the Proposed Rule; efforts to place sympathetic experts on the Roundtable; and advocacy directed at members of Congress and

- their staffs in connection with MoCRA and the Consolidated Appropriations Act, 2023. DOBS's regulatory advocacy is not incidental to its litigation practice; rather, it is a deliberate strategy to create a favorable regulatory environment that can be exploited in the courtroom.

COUNT I – PURE BILL OF DISCOVERY

16. A pure bill of discovery is an equitable remedy which “lies to obtain the disclosure of facts within the defendant’s knowledge, or deeds or writings or other things in his custody, in aid of the prosecution or defense of an action pending or about to be commenced in some other court.” *Publix Supermarkets, Inc. v. Frazier*, 696 So. 2d 1369, 1370 (Fla. 4th DCA 1997); *see Lewis v. Weaver*, 969 So. 2d 586, 587 (Fla. 4th DCA 2007) (“a true bill of discovery . . . allow[s] the injured party to ascertain whether a lawsuit may properly be asserted and under what theory or theories[;]” however “[t]here must of course be some basis for targeting a particular defendant....”); *see Vorbeck v. Betancourt*, 107 So. 3d 1142, 1145 (Fla. 3d DCA 2012) (The purpose of a pure bill is “to identify potential defendants and theories of liability and to obtain information necessary for meeting a condition precedent to filing suit.”).
-

17. To establish entitlement to a pure bill of discovery, a plaintiff must allege “(1) the nature and contents of documents or other matters in defendant’s possession or control, as to which discovery is [sought], (2) the matter or controversy to which the requested discovery relates, (3) the interest of each party in the subject of the inquiry, (4) [plaintiff’s] right to have the requested relief, (5) [plaintiff’s] title and interest, as well as [its] relationship to the discovery claimed, and (6) that the requested discovery is material and necessary to maintain [plaintiff’s] claims in the prospective litigation.” *Payne v. Beverly*, 958 So. 2d 1112, 1114 (Fla. 5th DCA 2007); *see also First Nat’l Bank of Mia. v. Dade-Broward Co.*, 171 So. 510, 511 (Fla. 1936). In addition, the plaintiff must show that “the evidence sought by discovery is essential to plaintiff[’s] cause of
-

action and cannot be otherwise procured.” *Fidelity & Deposit Co. of Md. v. Cone*, 179 So. 685, 688 (Fla. 1938). As set forth below, each element is satisfied.

18. **Nature and contents of the matters sought.** Upon information and belief, DOBS (or one or more others with whom DOBS has coordinated or from whom DOBS has obtained related information) has been actively engaged in communications with federal regulatory agencies and in lobbying efforts directly impacting the current legislative circumstances surrounding talc-based cosmetics and consumer products. Upon information and belief, DOBS possesses documents and information relating to such communications, lobbying activities, and coordination efforts concerning the regulation of talc in cosmetics and consumer products, including records of communications with HHS, the FDA, and the Executive Branch of the U.S. Government regarding: (a) the Consolidated Appropriations Act, 2023 (H.R. 2617; Pub. L. No. 117-328); (b) MoCRA; (c) the Proposed Rule and its withdrawal; and (d) the Roundtable. Upon information and belief, DOBS further possesses documents and records reflecting its efforts to influence, participate in, or respond to European health agencies’ assessments of a potential ban on talc.

19. Upon information and belief, DOBS also possesses records of coordination with trade organizations, advocacy groups, lobbying organizations, and other third parties regarding these regulatory matters, as well as records of payments made to experts, consultants, and scientists in connection with regulatory and lobbying efforts relating to talc used in cosmetics and consumer goods. These documents and records concern DOBS’s own conduct and relationships and are within DOBS’s possession, custody, or control. Plaintiff therefore brings this action to compel DOBS to produce these documents and to identify such regulatory communications and lobbying efforts.

20. **The matter or controversy to which the discovery relates.** The discovery sought relates directly to talc personal injury litigation in which DOBS represents plaintiffs against J&J in multiple jurisdictions and has used coordinated lobbying activities to directly advance litigation goals.

21. In the South Carolina Litigation, plaintiffs represented by DOBS have sought and obtained discovery from J&J concerning the company's lobbying activities, regulatory communications, and engagement with government agencies regarding recent cosmetics regulation. While Plaintiff took the position that such discovery was protected by various privileges and prejudicial and harassing in any event, DOBS pressed forward on its theory of relevance, and on October 2, 2026, the South Carolina court compelled the discovery. Thus, it is DOBS itself that has made the material relevant. To the extent DOBS (or one or more others with whom DOBS has coordinated or from whom DOBS has obtained related information) has engaged in lobbying, coordination with third-party organizations, or efforts to influence those same regulatory matters, those activities bear directly on both the discovery DOBS has obtained in the South Carolina Litigation and how DOBS will attempt to use that discovery in the Florida Litigation.

22. **The interest of each party.** Plaintiff's interest in this action is to obtain discovery necessary to present a complete and fair defense in talc litigation brought against it by DOBS's clients in Florida and elsewhere by presenting the full scope of lobbying activity by all interested parties, including DOBS, to the jury. DOBS's interest lies in its role as counsel to the claimants in that litigation and in the documents and information within its possession concerning its own regulatory advocacy – whether directly or through third parties. Plaintiff is a defendant in litigation pending across the country relating to allegations that individual claimants developed various

cancers due to their use of J&J talc-based cosmetic products allegedly contaminated with asbestos. DOBS serves as counsel for individual claimants in nearly one hundred such cases, including cases pending in South Carolina and Florida. If the individual claimants in either the South Carolina Litigation or the Florida Litigation intend to present Plaintiff's regulatory and lobbying activities to the jury as evidence of improper conduct, Plaintiff must be afforded the opportunity to show that DOBS itself engaged in similar advocacy directed at the same regulatory bodies and legislative actions, either directly or through funding and coordination with intermediaries and third-party organizations. Without this discovery, Plaintiff would be unable to demonstrate to the jury that lobbying on talc-related regulatory matters was a common and legitimate activity undertaken by multiple stakeholders, including the claimants' own counsel.

23. **Plaintiff's right to the requested relief.** Plaintiff's right to the requested relief derives from its due process right to present a fair and complete defense in pending talc and asbestos litigation brought against it by DOBS's clients, including the South Carolina Litigation and the Florida Litigation. The discovery sought cannot effectively be obtained through the procedural mechanisms available in those proceedings. DOBS is not a party to the underlying actions, so party discovery tools – interrogatories, requests for production, and requests for admission – cannot be directed to it. Discovery directed to the individual plaintiffs would not reach the information sought, because that information concerns DOBS's own regulatory and lobbying activity, which is not known to or possessed by the individual plaintiffs in any practical sense. A pure bill of discovery permits a single court to resolve, in one proceeding, Plaintiff's entitlement to narrowly defined, factual information concerning DOBS's own conduct.

24. **Plaintiff's title and interest and its relationship to the discovery.** Plaintiff's title and interest in the discovery claimed likewise derive from its right to present a complete defense

in the South Carolina Litigation, the Florida Litigation, and other talc litigation brought by DOBS's clients. Plaintiff has been subjected to extensive discovery demands by DOBS, including duplicative corporate representative deposition notices seeking testimony and documents on regulatory lobbying, expert compensation, and topics already exhaustively covered in prior depositions. The discovery sought in this matter will reveal whether DOBS itself has engaged in or benefited from the same type of lobbying, regulatory advocacy, and coordination with federal agencies that DOBS contends constitutes improper conduct by Plaintiff, thus enabling the jury to fairly evaluate the significance and context of any such activities.

25. **Materiality and necessity.** The requested discovery is material and necessary to Plaintiff's defense in the pending South Carolina Litigation and Florida Litigation. The evident purpose of DOBS's repeated requests for discovery relating to Plaintiff's regulatory activities and lobbying efforts is to portray Plaintiff before the jury as having acted improperly or sought to suppress regulatory oversight of talc-based cosmetics or consumer products. The discovery sought here is material to specific anticipated trial issues, including: (a) rebutting any argument that the lobbied regulatory agencies independently validate plaintiffs' causation theories, by establishing the provenance and sponsorship of the regulatory initiatives plaintiffs intend to rely upon; (b) testing the bias and compensation of experts who have participated both in regulatory advocacy and as retained litigation experts; and (c) providing necessary context if plaintiffs affirmatively characterize J&J's government contacts as evidence of wrongdoing. Absent this discovery, the jury would receive a distorted and incomplete account of the regulatory landscape, hearing only of Plaintiff's engagement while remaining unaware of any advocacy by opposing counsel directed at the very same governmental bodies.

26. **The discovery cannot be otherwise procured.** The discovery is not practically available through other means. DOBS's communications with regulators and third parties regarding the various regulatory matters described above, records of payments to experts and consultants in connection with regulatory advocacy, and records of coordination with third-party organizations are not public records and are not available through any other readily accessible source. The individual plaintiffs in the pending talc cases are not practical vehicles through which to obtain this discovery. The information concerns DOBS's own conduct and relationships, is not known to or possessed by the individual plaintiffs in any practical sense, and cannot reasonably be obtained from them. The individual plaintiffs' claims concern their alleged injuries from the use of talc-based cosmetic powder products, not the regulatory advocacy and lobbying activities of their counsel. Because DOBS appears in the pending talc litigation as counsel rather than as a party, ordinary discovery in those cases does not provide an effective mechanism to obtain the information sought. A pure bill of discovery is the only adequate and appropriate remedy to secure evidence that is critical to Plaintiff's defense.

27. A single proceeding is also necessary because the same information bears on every talc case DOBS is prosecuting against J&J. DOBS serves as counsel for claimants in nearly one hundred such cases across multiple jurisdictions. Pursuing non-party subpoenas to DOBS case by case would require serial, duplicative proceedings over the same records and risk inconsistent rulings on identical requests. Moreover, the relevance of DOBS's regulatory and lobbying activity does not arise from any individual plaintiff's claim; it arises from DOBS's strategy across its docket, as reflected in the identical lobbying and regulatory discovery DOBS has sought and obtained from J&J. A trial court presiding over a single personal injury action is poorly positioned to evaluate that cross-docket relevance and may view counsel's regulatory activity as collateral to

the individual claim before it. A pure bill of discovery allows one court to evaluate the relevance of, and Plaintiff's entitlement to, this discovery in its proper context and to issue a single ruling governing it.

WHEREFORE, Plaintiff respectfully requests this Court to:

1. compel DOBS, with respect to nonprivileged documents and information within its possession, custody, or control, and for the period from January 1, 2018 to the present:
 - a. to produce all documents and communications between (i) DOBS, any other plaintiffs' firm in talcum powder litigation, or any third party acting on behalf of or for the benefit of any of them; and (ii) HHS, FDA, the Executive Branch of the U.S. Government, any trade organization, trade association, advocacy group, lobbying organization, non-profit organization, or other third party regarding the Consolidated Appropriations Act, 2023 (H.R. 2617; Pub. L. No. 117-328); MoCRA; the Proposed Rule and its withdrawal; or the Roundtable, including all documents reflecting the fact or content of such communications;
 - b. to identify any and all efforts by DOBS, any other plaintiffs' firm in talcum powder litigation, or any third party acting on behalf of or for the benefit of any of them to lobby, influence, advocate for or against, or otherwise attempt to affect legislation, regulation, rulemaking, agency action, or proposals relating to talc used in cosmetics or consumer products, including but not limited to efforts directed at federal, state, or local government officials, legislators, regulators, or agencies, or any non-profit or standards-setting organizations;
 - c. to identify any and all payments, fees, contributions, donations, or other transfers of value made by or on behalf of DOBS, any other plaintiffs' firm in talcum powder

- litigation, or any third party acting on behalf of or for the benefit of any of them, to any third-party organization, lobbying group, advocacy organization, trade association, non-profit organization, political action committee, or other entity in connection with lobbying efforts, legislative activity, regulatory advocacy, or public policy initiatives relating to talc used in cosmetics or consumer products;
- d. to identify any and all payments, fees, contributions, donations, or other transfers of value made by or on behalf of DOBS, any other plaintiffs' firm in talcum powder litigation, or any third party acting on behalf of or for the benefit of any of them to any expert, consultant, scientist, or other individual in connection with regulatory, legislative, or lobbying efforts relating to talc, asbestos, cosmetics, or consumer product safety, as distinct from payments for litigation consulting or testimony;
 - e. to identify any and all efforts by DOBS, any other plaintiffs' firm in talcum powder litigation, or any third party acting on behalf of or for the benefit of any of them, to influence, participate in, or communicate regarding European health agencies' assessments of a potential ban on talc;
 - f. to produce all documents and communications with any member of Congress, Congressional staff, legislative aide, or government official regarding talc, asbestos, cosmetics regulation, or consumer product safety, including but not limited to any effort to influence legislation, regulation, or governmental policy;
 - g. to produce all documents and communications with any media organization, journalist, public relations firm, or communications consultant regarding lobbying efforts, regulatory advocacy, or public policy initiatives relating to talc, asbestos, cosmetics, or consumer product safety;

2. award Plaintiff its taxable costs; and
3. grant such other and further relief as this Court deems just and proper.

Dated: October 5, 2026

/s/ Joshua T. Fordin
Joshua T. Fordin
Florida Bar No. 125219
KIRKLAND & ELLIS LLP
830 Brickell Plaza
Miami, FL 33131
(305) 432-5684
josh.fordin@kirkland.com

CERTIFICATE OF SERVICE

I HEREBY CERTIFY that on October 5, 2026, the foregoing was filed electronically using the Court's electronic filing system, which will send notice and a copy of this filing to all counsel of record listed in the Florida Courts E-Filing Portal.

/s/ Joshua T. Fordin
Joshua T. Fordin

EXHIBIT 3

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934

Date of report (Date of earliest event reported):
October 13, 2026

Johnson & Johnson

(Exact name of registrant as specified in its charter)

New Jersey
(State or Other Jurisdiction
of Incorporation)

1-3215
(Commission File Number)

22-1024240
(IRS Employer
Identification No.)

One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933
(Address of Principal Executive Offices)
(Zip Code)

Registrant's telephone number, including area code:

732-524-0400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, Par Value \$1.00	JNJ	New York Stock Exchange
1.150% Notes Due November 2028	JNJ28	New York Stock Exchange
2.700% Notes due February 2029	JNJ29B	New York Stock Exchange
3.200% Notes Due June 2032	JNJ32	New York Stock Exchange
3.050% Notes due February 2033	JNJ33B	New York Stock Exchange
1.650% Notes Due May 2035	JNJ35	New York Stock Exchange
3.350% Notes Due June 2036	JNJ36A	New York Stock Exchange
3.350% Notes due February 2037	JNJ37B	New York Stock Exchange

3.550% Notes Due June 2044	JNJ44	New York Stock Exchange
3.600% Notes due February 2045	JNJ45	New York Stock Exchange
3.700% Notes due February 2055	JNJ55	New York Stock Exchange

Item 2.02 Results of operations and financial condition

On October 13, 2026, Johnson & Johnson (the “Company”) issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the third quarter ended September 27, 2026.

Item 9.01 Financial statements and exhibits

(d) Exhibits.

Exhibit No.	Description of Exhibit
99.1	Press Release dated October 13, 2026 for the period ended September 27, 2026
99.2	Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings for the fiscal third quarter and nine months
104	The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

JOHNSON & JOHNSON

(Registrant)

Date: October 13, 2026

By: /s/ **Robert J. Decker, Jr.**

Robert J. Decker, Jr.

Controller

(Principal Accounting Officer)

Exhibit 99.1

Media contact:
media-relations@its.jnj.com

Investor contact:
investor-relations@its.jnj.com

For immediate release

Johnson & Johnson reports Q3 2026 results, raises 2026 guidance

- 2026 Third-Quarter reported sales growth of 5.9% to \$25.4 Billion with operational growth of 6.0%* and adjusted operational growth of 6.1%*
- 2026 Third-Quarter earnings per share (EPS) of \$0.09 reflects a one-time special charge for the proposed talc litigation resolution, the acquisition of Firefly Bio, Inc., and the strategic collaboration with Sail Biomedicines; adjusted EPS* of \$2.59 also reflects the impact of these M&A deals
- Strong operational performance results in the Company increasing 2026 guidance with estimated reported sales of \$101.2 Billion or 7.4% at the midpoint and increasing adjusted EPS* guidance by \$0.06 to \$11.10 or 2.9% at the midpoint
- Significant innovation including the market authorization of OTTAVA as the world's first table-integrated soft tissue robotic system, approval of IMAAVY in warm autoimmune hemolytic anemia (wAIHA), and priority review for RYBREVANT FASPRO for advanced head and neck cancer

New Brunswick, N.J. (October 13, 2026) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2026.

"Johnson & Johnson's strong third-quarter performance and increased sequential growth reflect the accelerating momentum of our focused portfolio," said Joaquin Duato, Chairman and Chief Executive Officer. "In the third quarter, we advanced breakthroughs that will redefine care for patients, from delivering one of our most transformative MedTech innovations with OTTAVA to reporting positive Phase 3 results in multiple myeloma. This progress, together with strategic investments in high-growth areas, gives us clearer line of sight to double-digit growth by the end of the decade."

Overall financial results

(\$ in Millions, except EPS)	Q3		
	2026	2025	% Change
Reported Sales	\$25,399	\$23,993	5.9 %
Net Earnings	\$210	\$5,152	(95.9)%
EPS (diluted)	\$0.09	\$2.12	(95.8)%

Non-GAAP* (\$ in Millions, except EPS)	Q3		
	2026	2025	% Change
Operational Sales ^{1,2}			6.0 %
Adjusted Operational Sales ^{1,3}			6.1 %
Adjusted Net Earnings ^{1,4}	\$6,339	\$6,801	(6.8)%
Adjusted EPS (diluted) ^{1,4}	\$2.59	\$2.80	(7.5)%
Free Cash Flow ^{5,6}	~\$15,100	\$14,226	

¹ Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

² Excludes the impact of translational currency

³ Excludes the net impact of acquisitions and divestitures and translational currency

⁴ Excludes intangible amortization expense and special items

⁵ Non-GAAP financial measure; defined as cash flow from operating activities, less additions to property, plant and equipment. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings.

⁶ Third-quarter YTD 2026 is estimated as of October 13, 2026

Note: values may have been rounded

Regional sales results

Q3	% Change					
	2026	2025	Reported	Operational ^{1,2}	Currency	Adjusted Operational ^{1,3}
(\$ in Millions)						
U.S.	\$14,959	\$13,708	9.1 %	9.1	—	9.1
International	10,440	10,285	1.5	1.8	(0.3)	1.9
Worldwide	\$25,399	\$23,993	5.9 %	6.0	(0.1)	6.1

¹ Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

² Excludes the impact of translational currency

³ Excludes the net impact of acquisitions and divestitures and translational currency

Note: values may have been rounded

Segment sales results

Q3	% Change					
	2026	2025	Reported	Operational ^{1,2}	Currency	Adjusted Operational ^{1,3}
(\$ in Millions)						
Innovative Medicine	\$16,757	\$15,563	7.7 %	7.9	(0.2)	8.0
MedTech	8,642	8,430	2.5	2.5	0.0	2.5
Worldwide	\$25,399	\$23,993	5.9 %	6.0	(0.1)	6.1

¹ Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

² Excludes the impact of translational currency

³ Excludes the net impact of acquisitions and divestitures and translational currency

Note: values may have been rounded

Third-Quarter 2026 segment commentary:

Operational sales* reflected below excludes the impact of translational currency.

Innovative Medicine

Innovative Medicine worldwide operational sales grew 7.9%*, with divestitures negatively impacting growth by 10 basis points. Growth was primarily driven by TREMFYA and new products within Other in Immunology, DARZALEX, CARVYKTI, TECVAYLI, RYBRENT/VANZACLUZE, and ERLEADA in Oncology, and SPRAVATO and CAPLYTA in Neuroscience. Growth was partially offset by STELARA (an approximate 690 basis points impact), SIMPONI/SIMPONI ARIA, and REMICADE in Immunology, as well as OPSUMIT/OPSYNVI in Pulmonary Hypertension, and IMBRUVICA in Oncology.

MedTech

MedTech worldwide operational sales grew 2.5%*. Growth was primarily driven by electrophysiology products and Shockwave in Cardiovascular, contact lenses in Vision, as well as trauma in Orthopaedics.

Full-year 2026 guidance:

Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.

(\$ in Billions, except EPS)	October 2026	July 29, 2026
Adjusted Operational Sales ^{1,2}	6.4% – 6.8% / 6.6%	6.2% – 6.8% / 6.5%
Change vs. Prior Year / Mid-point		
Operational Sales ² / Mid-point	\$100.5B – \$100.9B / \$100.7B	\$100.3B – \$100.9B / \$100.6B
Change vs. Prior Year / Mid-point	6.7% – 7.1% / 6.9%	6.5% – 7.1% / 6.8%
Estimated Reported Sales ³ / Mid-point	\$101.0B – \$101.4B / \$101.2B	\$100.8B – \$101.4B / \$101.1B
Change vs. Prior Year / Mid-point	7.2% – 7.6% / 7.4%	7.0% – 7.6% / 7.3%
Adjusted Operational EPS (Diluted) ^{2,4} / Mid-point	\$10.95 – \$11.05 / \$11.00	\$10.86 – \$11.01 / \$10.94
Change vs. Prior Year / Mid-point	1.5% – 2.4% / 2.0%	0.7% – 2.1% / 1.4%
Adjusted EPS (Diluted) ^{3,4} / Mid-point	\$11.05 – \$11.15 / \$11.10	\$10.96 – \$11.11 / \$11.04
Change vs. Prior Year / Mid-point	2.4% – 3.3% / 2.9%	1.6% – 3.0% / 2.3%

¹ Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures

² Non-GAAP financial measure; excludes the impact of translational currency

³ Calculated using Euro Average Rate: October 2026 = \$1.15 and July 2026 = \$1.15 (Illustrative purposes only)

⁴ Non-GAAP financial measure; excludes intangible amortization expense and special items

Note: percentages may have been rounded

Other modeling considerations will be provided on the [webcast](#).

Notable announcements in the quarter:

The information contained in this section should be read together with Johnson & Johnson's other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations section of the company's website at [Investor News](#), as well as [Innovative Medicine Newsroom](#), [MedTech News & Events](#), and www.factsabouttalca.com.

Regulatory	Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses ¹	Press Release
	FDA approves IMAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients	Press Release
	Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer	Press Release
	Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System	Press Release

Data Releases	New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis ¹	Press Release
	Johnson & Johnson announces new ICOTYDE™ (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy ¹	Press Release
	Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis (gMG)	Press Release
	Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study	Press Release
	Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma	Press Release
	New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX Faspro® (daratumumab and hyaluronidase-hj) to redene long-term survival expectations in early line relapsed/refractory multiple myeloma	Press Release
	CAPLYTA® (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 study	Press Release
	RYBREVANT Faspro™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026	Press Release
	Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer	Press Release
	Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026	Press Release
	TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma	Press Release
Other	New Global Survey by Johnson & Johnson Finds Most Women Don't Connect Eye Health Changes with Menopause ¹	Press Release
	Johnson & Johnson's Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September	Press Release
	Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation	Press Release
	Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset	Press Release
	Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation	Press Release

¹Subsequent to the quarter

Webcast information:

Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the [Johnson & Johnson website](#). A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations section of the company's website at [events-and-presentations](#).

About Johnson & Johnson:

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at www.jnj.com.

Non-GAAP financial measures:

* "Operational sales growth" excluding the impact of translational currency, "adjusted operational sales growth" excluding the net impact of acquisitions and divestitures and translational currency, as well as "adjusted net earnings", "adjusted diluted earnings per share" and "adjusted operational diluted earnings per share" excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at [quarterly results](#).

Copies of the financial schedules accompanying this earnings release are available on the company's website at [quarterly results](#). These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, an [Innovative Medicine pipeline](#) of selected compounds in late stage development and a copy of today's earnings call presentation can also be found in the Investor Relations section of the company's website at [quarterly results](#).

Note to investors concerning forward-looking statements:

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; and the Company's ability to successfully separate the Company's Orthopaedics business and realize the anticipated benefits from the planned separation. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, investor.jnj.com, or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Exhibit 99.2

Johnson & Johnson and subsidiaries
Supplementary sales data

Sales to customers by geographic area	THIRD QUARTER				
	2026	2025	Percent Change		
			Total	Operations	Currency
U.S.	\$14,959	13,708	9.1 %	9.1	—
Europe	5,405	5,440	(0.6)	1.0	(1.6)
Western Hemisphere excluding U.S.	1,385	1,231	12.5	8.0	4.5
Asia-Pacific, Africa	3,650	3,614	1.0	1.0	0.0
International	10,440	10,285	1.5	1.8	(0.3)
Worldwide	\$25,399	23,993	5.9 %	6.0	(0.1)

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

Johnson & Johnson and subsidiaries

Supplementary sales data

Sales to customers by geographic area	NINE MONTHS				
	Percent Change				Currency
	2026	2025	Total	Operations	
U.S.	\$42,822	39,557	8.3 %	8.3	—
Europe	16,979	15,937	6.5	2.3	4.2
Western Hemisphere excluding U.S.	3,987	3,604	10.6	4.5	6.1
Asia-Pacific, Africa	10,983	10,531	4.3	3.6	0.7
International	31,949	30,072	6.2	3.0	3.2
Worldwide	\$74,771	69,629	7.4 %	6.0	1.4

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

Johnson & Johnson and subsidiaries
Supplementary sales data

(Unaudited; Dollars in Millions)	THIRD QUARTER				
			Percent Change		
Sales to customers by segment of business	2026	2025	Total	Operations	Currency
Innovative Medicine					
U.S.	\$ 10,447	9,402	11.1 %	11.1	—
International	6,310	6,161	2.4	3.0	(0.6)
	16,757	15,563	7.7	7.9	(0.2)
MedTech					
U.S.	4,512	4,306	4.8	4.8	—
International	4,130	4,124	0.1	0.1	0.0
	8,642	8,430	2.5	2.5	0.0
U.S.	14,959	13,708	9.1	9.1	—
International	10,440	10,285	1.5	1.8	(0.3)
Worldwide	\$ 25,399	23,993	5.9 %	6.0	(0.1)

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

Johnson & Johnson and subsidiaries
Supplementary sales data

Sales to customers by segment of business	NINE MONTHS				
			Percent Change		
	2026	2025	Total	Operations	Currency
Innovative Medicine					
U.S.	\$ 29,297	26,655	9.9 %	9.9	—
International	19,270	17,983	7.2	3.6	3.6
	48,567	44,638	8.8	7.4	1.4
MedTech					
U.S.	13,525	12,902	4.8	4.8	—
International	12,679	12,089	4.9	2.2	2.7
	26,204	24,991	4.9	3.5	1.4
U.S.	42,822	39,557	8.3	8.3	—
International	31,949	30,072	6.2	3.0	3.2
Worldwide	\$ 74,771	69,629	7.4 %	6.0	1.4

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

Johnson & Johnson and subsidiaries
Condensed consolidated statement of earnings

(Unaudited; in Millions Except Per Share Figures)

	THIRD QUARTER				
	2026		2025		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
Sales to customers	\$ 25,399	100.0	\$ 23,993	100.0	5.9
Cost of products sold	8,097	31.9	7,303	30.4	10.9
Gross Profit	17,302	68.1	16,690	69.6	3.7
Selling, marketing and administrative expenses	6,285	24.7	5,922	24.7	6.1
Research and development expense	4,652	18.3	3,672	15.3	26.7
In-process research and development impairments	339	1.4	—	—	
Interest (income) expense, net	31	0.1	18	0.1	
Other (income) expense, net	5,780	22.8	(478)	(2.0)	
Restructuring	181	0.7	63	0.3	
Earnings before provision for taxes on income	34	0.1	7,493	31.2	(99.5)
(Benefit from)/Provision for taxes on income	(176)	(0.7)	2,341	9.7	(107.5)
Net earnings	\$ 210	0.8	\$ 5,152	21.5	(95.9)
Net earnings per share (Diluted)	\$ 0.09		\$ 2.12		(95.8)
Average shares outstanding (Diluted)	2,448.6		2,428.6		
Effective tax rate	(517.6)%		31.2%		

Adjusted earnings before provision for taxes and net earnings ^{(1) (A)}

Earnings before provision for taxes on income	\$ 7,672	30.2	\$ 8,436	35.2	(9.1)
Net earnings	\$ 6,339	25.0	\$ 6,801	28.3	(6.8)
Net earnings per share (Diluted)	\$ 2.59		\$ 2.80		(7.5)
Effective tax rate	17.4%		19.4%		

⁽¹⁾ See Reconciliation of Non-GAAP Financial Measures.

^(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.

Johnson & Johnson and subsidiaries
Condensed consolidated statement of earnings

(Unaudited; in Millions Except Per Share Figures)

	NINE MONTHS				
	2026		2025		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
Sales to customers	\$ 74,771	100.0	\$ 69,629	100.0	7.4
Cost of products sold	24,254	32.4	22,288	32.0	8.8
Gross Profit	50,517	67.6	47,341	68.0	6.7
Selling, marketing and administrative expenses	18,751	25.1	16,923	24.3	10.8
Research and development expense	11,832	15.8	10,413	15.0	13.6
In-process research and development impairments	375	0.5	—	—	
Interest (income) expense, net	136	0.2	(62)	(0.1)	
Other (income) expense, net	6,405	8.6	(7,692)	(11.1)	
Restructuring	247	0.3	144	0.2	
Earnings before provision for taxes on income	12,771	17.1	27,615	39.7	(53.8)
Provision for taxes on income	1,792	2.4	5,927	8.6	(69.8)
Net earnings	\$ 10,979	14.7	\$ 21,688	31.1	(49.4)
Net earnings per share (Diluted)	\$ 4.49		\$ 8.94		(49.8)
Average shares outstanding (Diluted)	2,445.8		2,424.8		
Effective tax rate	14.0%		21.5%		

Adjusted earnings before provision for taxes and net earnings ^{(1) (A)}

Earnings before provision for taxes on income	\$ 24,153	32.3	\$ 24,635	35.4	(2.0)
Net earnings	\$ 20,034	26.8	\$ 20,206	29.0	(0.9)
Net earnings per share (Diluted)	\$ 8.19		\$ 8.33		(1.7)
Effective tax rate	17.1%		18.0%		

⁽¹⁾ See Reconciliation of Non-GAAP Financial Measures.

^(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.

Johnson & Johnson and subsidiaries

Reconciliation of non-GAAP financial measures

(Dollars in Millions Except Per Share Data)	THIRD QUARTER		NINE MONTHS	
	2026	2025	2026	2025
Net Earnings, after tax- as reported	\$210	\$5,152	\$10,979	\$21,688
<i>Pre-tax Adjustments</i>				
Litigation related	5,519	15	6,116	(6,894)
Intangible Asset Amortization expense	1,240	1,048	3,732	3,435
Restructuring related ¹	195	168	533	302
Orthopaedics separation related	369	—	746	—
Acquisition, integration and divestiture related	(34)	97	142	475
(Gains)/losses on securities	10	(387)	(262)	(327)
IPR&D impairments	339	—	375	—
Other	—	2	—	29
<i>Tax Adjustments</i>				
Tax impact on special item adjustments ²	(1,677)	(168)	(2,469)	826
Tax legislation and other tax related	168	874	142	672
Adjusted Net Earnings, after tax	\$6,339	\$6,801	\$20,034	\$20,206
Average shares outstanding (Diluted)	2,448.6	2,428.6	2,445.8	2,424.8
Adjusted net earnings per share (Diluted)	\$2.59	\$2.80	\$8.19	\$8.33
Operational adjusted net earnings per share (Diluted)	\$2.61		\$8.04	

Notes:

¹ In the fiscal second quarter of 2026, the Company initiated a supply chain restructuring program primarily in the Innovative Medicine segment to exit certain manufacturing locations as part of its optimization efforts to streamline operations. The program is expected to be substantially completed by the end of fiscal year 2029 with estimated costs between \$650 - \$750 million, and include site and supplier exit costs, decommissioning and asset impairment costs. Restructuring expenses of \$74 million in the fiscal third quarter of 2026 (\$274 million Q3 2026 YTD), were primarily related to asset impairments and exit costs.

In fiscal 2025, the Company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the network. Restructuring expenses of \$80 million were recorded in the fiscal third quarter of 2026 (\$194 million Q3 2026 YTD) and \$128 million in the fiscal third quarter of 2025 (\$157 million Q3 2025 YTD) primarily includes costs related to product exits. This program is expected to be substantially completed by the end of fiscal year 2026.

In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expenses of \$41 million in the fiscal third quarter of 2026 (\$65 million Q3 2026 YTD) and \$40 million in the fiscal third quarter of 2025 (\$145 million Q3 2025 YTD) includes costs related to market and product exits. This program will be completed as of Q4 2026 at a total cost of approximately \$1 billion.

² The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.

Johnson & Johnson and subsidiaries

Reconciliation of non-GAAP financial measures

Adjusted operational sales growth^(A)

Third quarter 2026 actual vs. 2025 actual

	Segments		
	Innovative Medicine	MedTech	Total
WW As Reported	7.7%	2.5%	5.9%
U.S.	11.1%	4.8%	9.1%
International	2.4%	0.1%	1.5%
WW Currency	(0.2)	0.0	(0.1)
U.S.	—	—	—
International	(0.6)	0.0	(0.3)
WW Operational	7.9%	2.5%	6.0%
U.S.	11.1%	4.8%	9.1%
International	3.0 %	0.1%	1.8%
All Other Acquisitions and Divestitures (A&D)	0.1	0.0	0.1
U.S.	0.0	0.0	0.0
International	0.2	0.0	0.1
WW Adjusted Operational Ex A&D	8.0%	2.5%	6.1%
U.S.	11.1%	4.8%	9.1%
International	3.2%	0.1%	1.9%

Note: Percentages are based on actual, non-rounded figures and may not sum

^(A) NON-GAAP FINANCIAL MEASURE "Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor's understanding of the Company's performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.

Johnson & Johnson and subsidiaries

Reconciliation of non-GAAP financial measures

Adjusted operational sales growth^(A)

Nine months 2026 actual vs. 2025 actual

	Segments		
	Innovative Medicine	MedTech	Total
WW As Reported	8.8%	4.9%	7.4%
U.S.	9.9%	4.8%	8.3%
International	7.2%	4.9%	6.2%
WW Currency	1.4	1.4	1.4
U.S.	—	—	—
International	3.6	2.7	3.2
WW Operational	7.4%	3.5%	6.0%
U.S.	9.9%	4.8%	8.3%
International	3.6%	2.2%	3.0%
Caplyta	(0.6)		(0.4)
U.S.	(1.0)		(0.7)
International	0.0		0.0
All Other Acquisitions and Divestitures (A&D)	0.1	0.1	0.1
U.S.	0.0	0.1	0.0
International	0.2	0.0	0.1
WW Adjusted Operational Ex A&D	6.9%	3.6%	5.7%
U.S.	8.9%	4.9%	7.6%
International	3.8%	2.2%	3.1%

Note: Percentages are based on actual, non-rounded figures and may not sum

^(A) NON-GAAP FINANCIAL MEASURE "Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor's understanding of the Company's performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.

Johnson & Johnson

Segment sales

(Dollars in Millions)

	THIRD QUARTER				
	2026	2025	% Change		
			Reported	Operational ⁽¹⁾	Currency
INNOVATIVE MEDICINE SEGMENT ⁽²⁾					
ONCOLOGY					
US	\$ 4,267	3,468	23.0 %	23.0 %	— %
Intl	3,335	3,060	9.0	9.5	(0.5)
WW	7,602	6,529	16.4	16.7	(0.3)
DARZALEX					
US	2,528	2,088	21.1	21.1	—
Intl	1,711	1,584	8.0	8.5	(0.5)
WW	4,239	3,672	15.4	15.6	(0.2)
CARVYKTI					
US	472	396	19.4	19.4	—
Intl	238	128	85.3	84.1	1.2
WW	710	524	35.5	35.2	0.3
TECVAYLI					
US	236	115	*	*	—
Intl	77	62	24.0	25.9	(1.9)
WW	312	177	76.6	77.3	(0.7)
TALVEY					
US	112	85	31.6	31.6	—
Intl	59	37	62.9	66.9	(4.0)
WW	171	122	40.9	42.1	(1.2)
RYBREVANT / LAZCLUZE					
US	201	136	47.9	47.9	—
Intl	119	61	94.5	98.3	(3.8)
WW	320	198	62.3	63.5	(1.2)
ERLEADA					
US	423	378	11.8	11.8	—
Intl	600	558	7.7	7.7	0.0
WW	1,023	936	9.4	9.4	0.0
IMBRUVICA					
US	145	211	(31.6)	(31.6)	—
Intl	420	483	(13.2)	(12.6)	(0.6)
WW	563	695	(18.8)	(18.4)	(0.4)
OTHER ONCOLOGY ⁽³⁾					
US	149	61	*	*	—
Intl	111	147	(24.4)	(23.9)	(0.5)
WW	262	207	26.3	26.7	(0.4)

See footnotes at end of schedule

Johnson & Johnson

Segment sales

(Dollars in Millions)

	THIRD QUARTER				
			% Change		
	2026	2025	Reported	Operational ⁽¹⁾	Currency
INNOVATIVE MEDICINE SEGMENT ⁽²⁾ (Continued)					
IMMUNOLOGY					
US	\$ 2,804	2,676	4.8 %	4.8 %	— %
Intl	1,417	1,493	(5.1)	(4.8)	(0.3)
WW	4,221	4,168	1.3	1.4	(0.1)
TREMFYA					
US	1,772	989	79.1	79.1	—
Intl	624	434	43.7	43.4	0.3
WW	2,396	1,424	68.3	68.2	0.1
SIMPONI / SIMPONI ARIA					
US	269	309	(13.2)	(13.2)	—
Intl	299	377	(20.6)	(20.3)	(0.3)
WW	568	687	(17.3)	(17.1)	(0.2)
REMICADE					
US	258	326	(20.8)	(20.8)	—
US Exports ⁽⁴⁾	12	19	(37.1)	(37.1)	—
Intl	124	132	(6.2)	(7.5)	1.3
WW	394	476	(17.3)	(17.6)	0.3
STELARA					
US	368	1,022	(64.0)	(64.0)	—
Intl	349	549	(36.5)	(35.5)	(1.0)
WW	716	1,570	(54.4)	(54.0)	(0.4)
OTHER IMMUNOLOGY					
US	126	12	*	*	—
Intl	21	0	*	*	*
WW	147	12	*	*	*
NEUROSCIENCE					
US	1,733	1,367	26.8	26.8	—
Intl	642	658	(2.4)	(1.7)	(0.7)
WW	2,375	2,024	17.3	17.6	(0.3)
SPRAVATO					
US	559	405	37.9	37.9	—
Intl	66	53	22.7	21.4	1.3
WW	624	459	36.1	36.0	0.1
CAPLYTA					
US	398	240	66.1	66.1	—
Intl	—	—	—	—	—
WW	398	240	66.1	66.1	—
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA					
US	739	664	11.4	11.4	—
Intl	258	267	(3.0)	(2.4)	(0.6)
WW	998	929	7.3	7.5	(0.2)

See footnotes at end of schedule

Johnson & Johnson

Segment sales

(Dollars in Millions)

	THIRD QUARTER				
	2026	2025	% Change		Currency
			Reported	Operational ⁽¹⁾	
INNOVATIVE MEDICINE SEGMENT ⁽²⁾ (Continued)					
CONCERTA / methylphenidate					
US	\$ 6	14	(56.3)%	(56.3)%	— %
Intl	138	127	8.1	8.9	(0.8)
WW	143	140	2.1	2.9	(0.8)
OTHER NEUROSCIENCE					
US	32	46	(30.6)	(30.6)	—
Intl	180	210	(14.3)	(13.1)	(1.2)
WW	212	256	(17.3)	(16.2)	(1.1)
PULMONARY HYPERTENSION (PH)					
US	588	815	(27.8)	(27.8)	—
Intl	309	300	2.9	4.1	(1.2)
WW	897	1,115	(19.5)	(19.2)	(0.3)
UPTRAVI					
US	383	392	(2.2)	(2.2)	—
Intl	100	92	8.9	8.4	0.5
WW	483	484	(0.1)	(0.2)	0.1
OPSUMIT / OPSYNOVI					
US	193	409	(52.8)	(52.8)	—
Intl	179	168	5.9	7.8	(1.9)
WW	372	578	(35.7)	(35.2)	(0.5)
OTHER PULMONARY HYPERTENSION					
US	12	13	(7.3)	(7.3)	—
Intl	30	39	(23.8)	(21.2)	(2.6)
WW	42	53	(19.7)	(17.7)	(2.0)
INFECTIOUS DISEASES (ID)					
US	317	326	(2.7)	(2.7)	—
Intl	496	501	(1.2)	(0.1)	(1.1)
WW	813	829	(1.8)	(1.1)	(0.7)
EDURANT / rilpivirine					
US	5	7	(31.6)	(31.6)	—
Intl	382	378	1.0	2.4	(1.4)
WW	386	385	0.4	1.8	(1.4)
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA					
US	307	315	(2.5)	(2.5)	—
Intl	74	81	(8.9)	(7.7)	(1.2)
WW	381	397	(3.8)	(3.6)	(0.2)
OTHER INFECTIOUS DISEASES					
US	5	4	29.9	29.9	—
Intl	40	42	(6.2)	(7.9)	1.7
WW	46	47	(3.0)	(4.5)	1.5

See footnotes at end of schedule

Johnson & Johnson

Segment sales

(Dollars in Millions)

	THIRD QUARTER				
	2026	2025	% Change		
			Reported	Operational ⁽¹⁾	Currency
INNOVATIVE MEDICINE SEGMENT ⁽²⁾ (Continued)					
CARDIOVASCULAR / METABOLISM / OTHER (CVM)					
US	\$ 736	750	(1.9)%	(1.9)%	— %
Intl	112	149	(24.3)	(23.8)	(0.5)
WW	849	899	(5.6)	(5.5)	(0.1)
XARELTO					
US	653	635	2.7	2.7	—
Intl	—	—	—	—	—
WW	653	635	2.7	2.7	—
OTHER					
US	84	115	(27.2)	(27.2)	—
Intl	112	149	(24.3)	(23.8)	(0.5)
WW	197	264	(25.5)	(25.3)	(0.2)
TOTAL PH, ID, CVM					
US	1,643	1,891	(13.2)	(13.2)	—
Intl	917	950	(3.5)	(2.5)	(1.0)
WW	2,560	2,843	(9.9)	(9.6)	(0.3)
TOTAL INNOVATIVE MEDICINE					
US	10,447	9,402	11.1	11.1	—
Intl	6,310	6,161	2.4	3.0	(0.6)
WW	\$16,757	15,563	7.7%	7.9%	(0.2)%

See footnotes at end of schedule

Johnson & Johnson

Segment sales

(Dollars in Millions)

	THIRD QUARTER				
	2026	2025	% Change		Currency
			Reported	Operational ⁽¹⁾	
MEDTECH SEGMENT⁽²⁾					
CARDIOVASCULAR					
US	\$ 1,397	1,306	7.0 %	7.0 %	—%
Intl	910	908	0.2	(0.2)	0.4
WW	2,307	2,213	4.3	4.1	0.2
<u>ELECTROPHYSIOLOGY</u>					
US	771	720	7.0	7.0	—
Intl	717	698	2.8	1.8	1.0
WW	1,487	1,418	4.9	4.4	0.5
<u>ABIOMED</u>					
US	335	336	(0.3)	(0.3)	—
Intl	78	86	(10.4)	(6.5)	(3.9)
WW	412	423	(2.3)	(1.5)	(0.8)
<u>SHOCKWAVE</u>					
US	261	220	18.8	18.8	—
Intl	64	59	9.3	11.2	(1.9)
WW	325	278	16.8	17.2	(0.4)
<u>OTHER CARDIOVASCULAR</u>					
US	31	30	3.6	3.6	—
Intl	50	65	(21.9)	(23.1)	1.2
WW	81	95	(13.9)	(14.7)	0.8
SURGERY					
US	1,070	1,031	3.7	3.7	—
Intl	1,459	1,511	(3.4)	(4.2)	0.8
WW	2,528	2,542	(0.6)	(1.0)	0.4
<u>ADVANCED</u>					
US	500	477	5.1	5.1	—
Intl	654	688	(5.0)	(5.7)	0.7
WW	1,155	1,165	(0.9)	(1.3)	0.4
<u>GENERAL</u>					
US	568	555	2.4	2.4	—
Intl	805	823	(2.2)	(3.0)	0.8
WW	1,373	1,378	(0.3)	(0.8)	0.5

See footnotes at end of schedule

Johnson & Johnson
Segment sales

(Dollars in Millions)

	THIRD QUARTER				
	2026	2025	% Change		Currency
			Reported	Operational ⁽¹⁾	
MEDTECH SEGMENT⁽²⁾(Continued)					
VISION					
US	\$596	571	4.3 %	4.3 %	—%
Intl	865	828	4.4	5.6	(1.2)
WW	1,461	1,400	4.4	5.1	(0.7)
<u>CONTACT LENSES / OTHER</u>					
US	465	456	1.9	1.9	—
Intl	588	562	4.7	6.2	(1.5)
WW	1,053	1,018	3.5	4.3	(0.8)
<u>SURGICAL</u>					
US	132	116	13.6	13.6	—
Intl	276	266	3.8	4.3	(0.5)
WW	408	383	6.8	7.1	(0.3)
ORTHOPAEDICS					
US	1,448	1,396	3.8	3.8	—
Intl	898	878	2.2	2.9	(0.7)
WW	2,345	2,274	3.2	3.4	(0.2)
<u>HIPS</u>					
US	271	262	3.5	3.5	—
Intl	148	144	2.6	3.0	(0.4)
WW	419	405	3.1	3.3	(0.2)
<u>KNEES</u>					
US	221	216	2.1	2.1	—
Intl	165	160	3.0	4.4	(1.4)
WW	386	377	2.5	3.1	(0.6)
<u>TRAUMA</u>					
US	555	512	8.6	8.6	—
Intl	288	281	2.4	2.8	(0.4)
WW	844	793	6.4	6.5	(0.1)
<u>SPINE, SPORTS & OTHER</u>					
US	401	406	(1.2)	(1.2)	—
Intl	296	293	1.3	2.0	(0.7)
WW	697	698	(0.1)	0.1	(0.2)
TOTAL MEDTECH					
US	4,512	4,306	4.8	4.8	—
Intl	4,130	4,124	0.1	0.1	0.0
WW	\$8,642	8,430	2.5%	2.5%	0.0 %

See footnotes at end of schedule

Johnson & Johnson

Segment sales

(Dollars in Millions)

	NINE MONTHS				
	2026	2025	% Change		
			Reported	Operational ⁽¹⁾	Currency
INNOVATIVE MEDICINE SEGMENT ⁽²⁾					
ONCOLOGY					
US	\$11,951	9,866	21.1 %	21.1 %	—%
Intl	10,030	8,652	15.9	11.9	4.0
WW	21,981	18,519	18.7	16.8	1.9
DARZALEX					
US	7,171	5,934	20.9	20.9	—
Intl	5,239	4,514	16.1	11.9	4.2
WW	12,410	10,448	18.8	17.0	1.8
CARVYKTI					
US	1,377	1,072	28.5	28.5	—
Intl	587	260	*	*	*
WW	1,964	1,332	47.4	45.5	1.9
TECVAYLI					
US	549	334	64.4	64.4	—
Intl	225	160	40.6	37.7	2.9
WW	774	494	56.7	55.7	1.0
TALVEY					
US	325	235	38.1	38.1	—
Intl	172	79	*	*	*
WW	497	314	58.3	57.5	0.8
RYBREVANT / LAZCLUZE					
US	566	388	46.1	46.1	—
Intl	300	130	*	*	*
WW	866	518	67.4	67.5	(0.1)
ERLEADA					
US	1,161	1,048	10.8	10.8	—
Intl	1,806	1,567	15.3	10.8	4.5
WW	2,967	2,615	13.5	10.8	2.7
IMBRUVICA					
US	437	685	(36.3)	(36.3)	—
Intl	1,386	1,453	(4.7)	(8.7)	4.0
WW	1,822	2,139	(14.8)	(17.5)	2.7
OTHER ONCOLOGY ⁽³⁾					
US	365	171	*	*	—
Intl	314	488	(35.7)	(36.0)	0.3
WW	680	659	3.2	2.9	0.3

See footnotes at end of schedule

Johnson & Johnson

Segment sales

(Dollars in Millions)

	NINE MONTHS				
			% Change		
	2026	2025	Reported	Operational ⁽¹⁾	Currency
INNOVATIVE MEDICINE SEGMENT ⁽²⁾ (Continued)					
IMMUNOLOGY					
US	\$7,031	7,377	(4.7)%	(4.7)%	—%
Intl	4,414	4,492	(1.7)	(4.9)	3.2
WW	11,445	11,868	(3.6)	(4.8)	1.2
TREMFYA					
US	4,279	2,384	79.5	79.5	—
Intl	1,771	1,181	49.9	44.7	5.2
WW	6,050	3,566	69.7	67.9	1.8
SIMPONI / SIMPONI ARIA					
US	798	906	(11.9)	(11.9)	—
Intl	1,035	1,130	(8.4)	(11.4)	3.0
WW	1,833	2,036	(10.0)	(11.6)	1.6
REMICADE					
US	742	923	(19.6)	(19.6)	—
US Exports ⁽⁴⁾	40	63	(36.6)	(36.6)	—
Intl	372	413	(9.8)	(12.9)	3.1
WW	1,154	1,398	(17.5)	(18.4)	0.9
STELARA					
US	924	3,081	(70.0)	(70.0)	—
Intl	1,188	1,768	(32.8)	(34.9)	2.1
WW	2,112	4,848	(56.4)	(57.2)	0.8
OTHER IMMUNOLOGY					
US	249	21	*	*	—
Intl	48	0	*	*	*
WW	297	21	*	*	*
NEUROSCIENCE					
US	4,886	3,712	31.6	31.6	—
Intl	2,001	2,011	(0.5)	(3.0)	2.5
WW	6,887	5,722	20.3	19.5	0.8
SPRAVATO					
US	1,479	1,047	41.3	41.3	—
Intl	197	146	34.8	28.1	6.7
WW	1,676	1,193	40.5	39.7	0.8
CAPLYTA ⁽⁵⁾					
US	1,029	451	*	*	—
Intl	—	—	—	—	—
WW	1,029	451	*	*	—
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA					
US	2,235	2,021	10.6	10.6	—
Intl	816	804	1.5	(0.8)	2.3
WW	3,051	2,824	8.0	7.4	0.6
CONCERTA / methylphenidate					
US	40	76	(47.3)	(47.3)	—
Intl	386	376	2.4	1.1	1.3

WW	425	452	(5.9)	(7.0)	1.1
----	-----	-----	-------	-------	-----

See footnotes at end of schedule

Johnson & Johnson

Segment sales

(Dollars in Millions)

	NINE MONTHS				
			% Change		
	2026	2025	Reported	Operational ⁽¹⁾	Currency
INNOVATIVE MEDICINE SEGMENT ⁽²⁾ (Continued)					
OTHER NEUROSCIENCE					
US	\$ 104	119	(12.6)%	(12.6)%	— %
Intl	602	684	(12.0)	(14.5)	2.5
WW	706	803	(12.1)	(14.2)	2.1
PULMONARY HYPERTENSION (PH)					
US	2,233	2,358	(5.3)	(5.3)	—
Intl	942	895	5.2	2.9	2.3
WW	3,175	3,253	(2.4)	(3.0)	0.6
UPTRAVI					
US	1,154	1,139	1.3	1.3	—
Intl	306	272	12.7	7.9	4.8
WW	1,460	1,411	3.5	2.6	0.9
OPSUMIT / OPSYNOVI					
US	1,042	1,175	(11.3)	(11.3)	—
Intl	538	507	6.0	4.4	1.6
WW	1,580	1,682	(6.1)	(6.6)	0.5
OTHER PULMONARY HYPERTENSION					
US	37	44	(15.5)	(15.5)	—
Intl	98	116	(15.6)	(15.3)	(0.3)
WW	135	160	(15.6)	(15.4)	(0.2)
INFECTIOUS DISEASES (ID)					
US	959	961	(0.2)	(0.2)	—
Intl	1,506	1,472	2.3	(1.7)	4.0
WW	2,465	2,434	1.3	(1.1)	2.4
EDURANT / rilpivirine					
US	15	21	(30.1)	(30.1)	—
Intl	1,131	1,082	4.5	0.6	3.9
WW	1,145	1,103	3.8	0.0	3.8
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA					
US	937	932	0.6	0.6	—
Intl	259	264	(1.9)	(6.2)	4.3
WW	1,196	1,196	0.0	(0.9)	0.9
OTHER INFECTIOUS DISEASES					
US	7	8	(11.4)	(11.4)	—
Intl	116	126	(8.0)	(11.7)	3.7
WW	124	135	(8.2)	(11.7)	3.5

See footnotes at end of schedule

Johnson & Johnson
Segment sales

(Dollars in Millions)

	NINE MONTHS				
	2026	2025	% Change		Currency
			Reported	Operational ⁽¹⁾	
INNOVATIVE MEDICINE SEGMENT ⁽²⁾ (Continued)					
CARDIOVASCULAR / METABOLISM / OTHER (CVM)					
US	\$ 2,235	2,381	(6.1)%	(6.1)%	— %
Intl	378	461	(17.9)	(20.9)	3.0
WW	2,614	2,842	(8.0)	(8.5)	0.5
XARELTO					
US	1,959	1,946	0.7	0.7	—
Intl	—	—	—	—	—
WW	1,959	1,946	0.7	0.7	—
OTHER					
US	276	435	(36.5)	(36.5)	—
Intl	378	461	(17.9)	(20.9)	3.0
WW	655	896	(26.9)	(28.5)	1.6
TOTAL PH, ID, CVM					
US	5,428	5,700	(4.8)	(4.8)	—
Intl	2,826	2,828	(0.1)	(3.4)	3.3
WW	8,254	8,529	(3.2)	(4.3)	1.1
TOTAL INNOVATIVE MEDICINE					
US	29,297	26,655	9.9	9.9	—
Intl	19,270	17,983	7.2	3.6	3.6
WW	\$ 48,567	44,638	8.8%	7.4%	1.4%

See footnotes at end of schedule

Johnson & Johnson
Segment sales

(Dollars in Millions)

	NINE MONTHS				
	2026	2025	% Change		Currency
			Reported	Operational ⁽¹⁾	
MEDTECH SEGMENT⁽²⁾					
CARDIOVASCULAR					
US	\$ 4,222	3,931	7.4 %	7.4 %	— %
Intl	2,866	2,698	6.2	3.4	2.8
WW	7,088	6,629	6.9	5.8	1.1
<u>ELECTROPHYSIOLOGY</u>					
US	2,290	2,145	6.8	6.8	—
Intl	2,219	2,064	7.5	4.3	3.2
WW	4,509	4,209	7.1	5.6	1.5
<u>ABIOMED</u>					
US	1,066	1,035	3.0	3.0	—
Intl	275	256	7.2	5.4	1.8
WW	1,340	1,291	3.8	3.5	0.3
<u>SHOCKWAVE</u>					
US	771	659	17.0	17.0	—
Intl	194	169	14.8	15.1	(0.3)
WW	965	828	16.6	16.6	0.0
<u>OTHER CARDIOVASCULAR</u>					
US	96	93	3.2	3.2	—
Intl	177	209	(15.0)	(17.7)	2.7
WW	273	302	(9.4)	(11.3)	1.9
SURGERY					
US	3,210	3,076	4.3	4.3	—
Intl	4,483	4,417	1.5	(1.6)	3.1
WW	7,692	7,493	2.7	0.8	1.9
<u>ADVANCED</u>					
US	1,476	1,411	4.7	4.7	—
Intl	1,991	1,991	0.0	(2.9)	2.9
WW	3,467	3,402	1.9	0.2	1.7
<u>GENERAL</u>					
US	1,733	1,666	4.0	4.0	—
Intl	2,492	2,426	2.7	(0.6)	3.3
WW	4,225	4,092	3.3	1.3	2.0

See footnotes at end of schedule

Johnson & Johnson

Segment sales

(Dollars in Millions)

	NINE MONTHS				
	2026	2025	% Change		Currency
			Reported	Operational ⁽¹⁾	
MEDTECH SEGMENT⁽²⁾(Continued)					
VISION					
US	\$1,740	1,694	2.7 %	2.7 %	— %
Intl	2,537	2,354	7.8	6.3	1.5
WW	4,277	4,048	5.6	4.8	0.8
<u>CONTACT LENSES / OTHER</u>					
US	1,378	1,337	3.1	3.1	—
Intl	1,669	1,565	6.6	5.5	1.1
WW	3,047	2,902	5.0	4.4	0.6
<u>SURGICAL</u>					
US	363	358	1.4	1.4	—
Intl	867	789	10.0	8.0	2.0
WW	1,230	1,147	7.3	5.9	1.4
ORTHOPAEDICS					
US	4,353	4,200	3.6	3.6	—
Intl	2,794	2,620	6.6	3.5	3.1
WW	7,146	6,820	4.8	3.6	1.2
<u>HIPS</u>					
US	831	796	4.4	4.4	—
Intl	465	440	5.7	2.1	3.6
WW	1,296	1,235	4.9	3.6	1.3
<u>KNEES</u>					
US	688	673	2.2	2.2	—
Intl	528	482	9.7	7.1	2.6
WW	1,216	1,155	5.3	4.2	1.1
<u>TRAUMA</u>					
US	1,623	1,515	7.1	7.1	—
Intl	880	818	7.6	4.4	3.2
WW	2,504	2,333	7.3	6.2	1.1
<u>SPINE, SPORTS & OTHER</u>					
US	1,211	1,216	(0.4)	(0.4)	—
Intl	920	881	4.5	1.5	3.0
WW	2,131	2,096	1.7	0.4	1.3
TOTAL MEDTECH					
US	13,525	12,902	4.8	4.8	—
Intl	12,679	12,089	4.9	2.2	2.7
WW	\$26,204	24,991	4.9%	3.5%	1.4 %

Note: Column and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

* Percentage greater than 100% or not meaningful

⁽¹⁾ Operational growth excludes the effect of translational currency

⁽²⁾ Unaudited

⁽³⁾ Includes the sales of ZYTIGA which were previously disclosed separately

⁽⁴⁾ Reported as U.S. sales

⁽⁵⁾ Acquired with Intra-Cellular Therapies on April 2, 2025

EXHIBIT 4

Facts About Talc



The facts on talcum powder safety

Decades of independent scientific testing have confirmed that talc is safe, does not contain asbestos and does not cause cancer.

We recognize the anxiety and confusion that on-going litigation has caused, and that many people who have used talc-based products have questions. This site is designed to share the facts about talc and these cases, and why Johnson & Johnson continues to stand behind the safety of talc.

For clarity, Johnson & Johnson does not sell over-the-counter medicines or consumer products, including Johnson's Baby Powder. The company is exclusively focused on developing and manufacturing innovative healthcare solutions for the world's toughest diseases including novel medicines and medical technologies.

Consumer brands including Tylenol, Band-Aid Brand Adhesive Bandages and Johnson's Baby are owned by Kenvue Inc., which has been an independent publicly traded company since August 2023. For a complete list of products, please see [here](#) and visit Kenvue for more information. As a part of that separation, Kenvue retained the responsibility and any purported liability for talc related litigation outside of the United States and Canada.

About talcum powder

What is talcum powder?

Talcum powder is the refined, powdery form of the softest mineral on earth: talc. Talc is an “inert” ingredient, meaning it does not generate a chemical reaction when ingested or used on the skin. People have taken advantage of its natural smoothness, safety and absorbency since ancient Egyptian times.¹

Where does our talc come from?

Talc is found in rock deposits all over the planet and is mined like many other minerals. Only pharmaceutical grade talc is used in our baby powder.

How is talcum powder made?

Once it is taken from the earth, talc is partially crushed, sorted and assigned a grade. The talc ore that meets our standards is then milled to a powder, tested for particle size and confirmed to meet Johnson & Johnson's purity requirements.

Does Johnson & Johnson still sell talc?

Johnson & Johnson does not sell over-the-counter medicines or consumer products, including Johnson's Baby Powder. The company is exclusively focused on developing and manufacturing innovative healthcare solutions for the world's toughest diseases including [novel medicines](#) and [medical technologies](#).

Talc is safe



Talc has been used for centuries

It's the softest mineral on earth, and has been used for a variety of applications dating back to ancient Egypt.²



Talc is more common than you think

It's in the foods we eat, including chewing gum, rice and olive oil, and many products we use every day (like makeup, soap and antiperspirant.)^{1,2,3}





Talc is safe

Research, clinical evidence and nearly 40 years of studies by independent medical experts around the world continue to support the safety of talc.



Talc does not cause cancer

The National Cancer Institute's Physician Data Query Editorial Board concluded that the weight of evidence does not support an association between perineal talc exposure and increased risk of ovarian cancer.

Decades of safety

We continue to use talc in our products because decades of science have reaffirmed its safety. Your trust in Johnson's Baby Products and your confidence using them every day is a huge responsibility – that's why we only use ingredients that are deemed safe to use by the latest science.

Research, clinical evidence and over 40 years of studies by medical experts around the world continue to support the safety of cosmetic talc. Health authorities around the world have reviewed the data on talc, and it is used widely across the globe.

Even with talc's long history of safe use in consumer products, some have questioned whether using talcum powder can increase a person's risk of developing cancer. Recently, there have been questions raised as to whether the talc used in consumer products is contaminated with asbestos. The weight of the science does not support any claim that our talc products cause cancer.

Thousands of tests repeatedly confirm that our consumer talc products do not contain asbestos. Our talc comes from ore sources confirmed to meet our stringent specifications. Not only is our talc routinely tested to ensure it does not contain asbestos, our talc has also been tested and confirmed to be asbestos-free by a range of independent laboratories and universities.

You've probably read news stories about lawsuits claiming Johnson's Baby Powder can cause ovarian cancer or mesothelioma

Johnson's uses only pure, pharmaceutical grade talc. We test every lot to ensure it. But don't take our word for it. Explore the facts and make up your own mind.

More facts about talc

Explore the science

Review the evidence

News

References

- ¹ Industrial Minerals Association. "What is Talc." http://www.ima-na.org/?page=what_is_talc
- ² EARTH magazine. Mineral Resource of the Month. <http://www.earthmagazine.org/article/mineral-resource-month-talc>
- ³ Geology.com. Talc: The Softest Mineral. <http://geology.com/minerals/talc.shtml>
- ⁴ Gertig, Prospective Study of Talc Use and Ovarian Cancer, Journal of the National Cancer Institute, Nurses Health Study. <http://jnci.oxfordjournals.org/content/92/3/249.full>
- ⁵ Gates, Risk Factors for Epithelial Ovarian Cancer by Histologic Subtype, American Journal of Epidemiology. <http://aje.oxfordjournals.org/content/171/1/45.full>
- ⁶ Houghton, Perineal Powder Use and Risk of Ovarian Cancer, Journal of the National Cancer Institute, Women's Health Initiative. <http://jnci.oxfordjournals.org/content/106/9/dju208.full>
- ⁷ Gonzalez, Douching, Talc Use and Risk of Ovarian Cancer, Epidemiology. <https://www.ncbi.nlm.nih.gov/pubmed/27327020>
- ⁸ Cancer.org. Talcum Powder and Cancer. <http://www.cancer.org/cancer/cancercauses/othercarcinogens/athome/talcum-powder-and-cancer>
- ⁹ O'Brien, Tworoger, Harris, et al., Association of Powder Use in the Genital Area With Risk of Ovarian Cancer.

<https://jamanetwork.com/journals/jama/article-abstract/2758452>

[Privacy policy](#) | [Legal notice](#) | [Do not sell or share my personal information](#) | [Limit the use of my sensitive personal information](#)
This site is intended for use by residents of the United States and follows U.S. data protection rules.

© 2023 Johnson & Johnson Services, Inc.